What Else Can Weight Loss Medication Treat?
Eli Lilly’s blockbuster diabetes drug Mounjaro and weight-loss therapy Zepbound, as well as Novo Nordisk’s rival medicines Ozempic and Wegovy, are being studied to see whether they can improve health in other ways. The U.S. Food and Drug Administration on Friday approved Novo’s Wegovy for lowering the risk of stroke and heart attack in overweight or obese adults who do not have diabetes. Below are other conditions obesity treatments are being tested against:
Alcohol Addiction: A study by the University of Copenhagen’s Psychiatric Centre Rigshospitalet is investigating whether semaglutide, sold as Novo’s Wegovy and Ozempic, can help reduce alcohol intake in 108 patients diagnosed with alcohol use disorder and obesity.
Alzheimer’s disease: Novo Nordisk has begun a trial testing semaglutide in patients with early Alzheimer’s disease. The study, which will enrol 1,840 patients, could reach primary completion as early as 2025.
Excerpted from CTV News
